NCT07560449 QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms Status NOT_YET_RECRUITING Phase PHASE2
NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma Status NOT_YET_RECRUITING Phase PHASE3
NCT07532525 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma Status NOT_YET_RECRUITING Phase PHASE1
NCT07523737 Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma Status RECRUITING Phase PHASE2
NCT07463807 Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT07452198 A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE3
NCT07391657 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) Status RECRUITING Phase PHASE3
NCT07257510 Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma Status RECRUITING Phase NA
NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) Status RECRUITING Phase PHASE2
NCT07222761 A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Status RECRUITING Phase PHASE3
NCT07150104 Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT07138209 A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE3
NCT07096778 Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Status RECRUITING Phase PHASE2
NCT07018401 Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study Status ACTIVE_NOT_RECRUITING Phase N/A
NCT07018050 Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma Status RECRUITING Phase PHASE2
NCT07015021 The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients Status NOT_YET_RECRUITING Phase NA
NCT06956170 All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06953960 A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) Status RECRUITING Phase PHASE1/PHASE2
NCT06948084 Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Status NOT_YET_RECRUITING Phase PHASE2
NCT06768489 A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma Status RECRUITING Phase PHASE1